FY2025 EPS Estimates for Kura Oncology, Inc. Boosted by Analyst (NASDAQ:KURA)

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) – Stock analysts at Wedbush lifted their FY2025 EPS estimates for shares of Kura Oncology in a research note issued to investors on Thursday, May 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $2.45 per share for the year, up from their previous forecast of $2.44. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.38) per share. Wedbush also issued estimates for Kura Oncology’s FY2027 earnings at $8.27 EPS.

A number of other analysts have also issued reports on KURA. StockNews.com started coverage on shares of Kura Oncology in a research note on Thursday, March 16th. They set a “sell” rating on the stock. Stifel Nicolaus lowered their price target on Kura Oncology from $25.00 to $24.00 in a report on Thursday. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price target on shares of Kura Oncology in a report on Monday, April 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Friday, February 24th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Kura Oncology Stock Down 1.3 %

Shares of KURA opened at $12.24 on Friday. The company has a current ratio of 18.56, a quick ratio of 18.56 and a debt-to-equity ratio of 0.02. The firm has a market cap of $837.69 million, a P/E ratio of -6.03 and a beta of 0.89. The company’s 50-day moving average price is $11.50 and its 200 day moving average price is $12.84. Kura Oncology has a 12-month low of $9.49 and a 12-month high of $19.93.

Kura Oncology (NASDAQ:KURA – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.09.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently modified their holdings of the company. Raymond James & Associates raised its position in Kura Oncology by 18.6% in the first quarter. Raymond James & Associates now owns 17,598 shares of the company’s stock worth $283,000 after acquiring an additional 2,757 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Kura Oncology by 47.3% in the 1st quarter. MetLife Investment Management LLC now owns 34,950 shares of the company’s stock worth $562,000 after buying an additional 11,227 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Kura Oncology by 38.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,070,685 shares of the company’s stock worth $17,217,000 after buying an additional 296,175 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kura Oncology by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 3,330,346 shares of the company’s stock worth $53,553,000 after purchasing an additional 56,638 shares during the period. Finally, Bridgefront Capital LLC purchased a new position in shares of Kura Oncology in the 1st quarter worth about $180,000.

Kura Oncology Company Profile

(Get Rating)

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.